1-15 of 15
Fei Su
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3251: QTOLIMOD: A specific TLR9 agonist nanomedicine with high anti-solid tumor activity

Fei Su, Jun Bai, Chen Li, Yujing Wu, Jing Li, Xiaobin Zhao, Yongsheng Yang, Robert J. Lee
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3251.
https://doi.org/10.1158/1538-7445.AM2024-3251
Published: 22 March 2024
View article titled, Abstract 3251: QTOLIMOD: A specific TLR9 agonist nanomedicine with high anti-solid tumor activity
Journal Articles

Abstract 939: Comprehensive genomic and transcriptomic analysis to guide therapy for patients with metastatic solid tumors

Burak Uzunparmak, Fei Su, Amber M. Johnson, Krystle Nomie, Nathan Fowler, Lile Kontselidze, Aleksander Bagaev, Anna Butusova, Ecaterina E. Dumbrava, Jordi Rodon-Ahnert, Siqing Fu, David S. Hong, Timothy A. Yap, Aung Naing, Sarina A. Piha-Paul, Daniel D. Karp, Paula R. Pohlmann, Apostolia M. Tsimberidou, Keyur P. Patel, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 939.
https://doi.org/10.1158/1538-7445.AM2024-939
Published: 22 March 2024
View article titled, Abstract 939: Comprehensive genomic and transcriptomic analysis to guide therapy for patients with metastatic solid tumors
Journal Articles

Abstract 392: Patient-specific, tiered, variant-level actionability correlates with functional effect in growth survival assay

Amber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, Julia Castillo, Bianca Amador, Vijaykumar Holla, Thuy Vu, Le Huang, Fei Su, Sunhee Kim, Jia Zeng, Md Abu Shufean, Tara Conway, Kenna R. Shaw, Timothy A. Yap, Jordi Rodon, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 392.
https://doi.org/10.1158/1538-7445.AM2021-392
Published: 01 July 2021
View article titled, Abstract 392: Patient-specific, tiered, variant-level actionability correlates with functional effect in growth survival assay
Journal Articles

Abstract 2710: The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers

Timothy Philip DiPeri, Kurt W. Evans, Ching-Wei D. Tzeng, Lawrence Kwong, Michael P. Kahle, Xiaofeng Zheng, Dali Li, Hop S. Tran Cao, Thuy Vu, Sunhee Kim, Fei Su, Bryce Kirby, Chetna Wathoo, Gabriela Raso, Yasmin Rizvi, Huamin Wang, Filip Janku, Kenna Shaw, Timothy Yap, Milind Javle, Jordi Rodon, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2710.
https://doi.org/10.1158/1538-7445.AM2021-2710
Published: 01 July 2021
View article titled, Abstract 2710: The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers
Journal Articles

Proinflammatory CXCL12–CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice

Achinto Saha, Songyeon Ahn, Jorge Blando, Fei Su, Mikhail G. Kolonin, John DiGiovanni
Journal: Cancer Research
Cancer Res (2017) 77 (18): 5158–5168.
https://doi.org/10.1158/0008-5472.CAN-17-0284
Published: 14 September 2017
View article titled, Proinflammatory CXCL12–CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice
Open the PDF for Proinflammatory CXCL12–CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice in another window
Includes: Supplementary data
Journal Articles

Abstract 2346: Preclinical selectivity profile of the CDK4/6 inhibitor ribociclib (LEE011) compared with that of palbociclib and abemaciclib

Ralph Tiedt, Scott Delach, Steven Kovats, Thomas Horn, Michael Acker, Barbara Schacher Engstler, Giordano Caponigro, Fei Su
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2346.
https://doi.org/10.1158/1538-7445.AM2017-2346
Published: 01 July 2017
View article titled, Abstract 2346: Preclinical selectivity profile of the CDK4/6 inhibitor ribociclib (LEE011) compared with that of palbociclib and abemaciclib
Journal Articles

Gain of Glucose-Independent Growth upon Metastasis of Breast Cancer Cells to the Brain

Jinyu Chen, Ho-Jeong Lee, Xuefeng Wu, Lei Huo, Sun-Jin Kim, Lei Xu, Yan Wang, Junqing He, Lakshmi R. Bollu, Guang Gao, Fei Su, James Briggs, Xiaojing Liu, Tamar Melman, John M. Asara, Isaiah J. Fidler, Lewis C. Cantley, Jason W. Locasale, Zhang Weihua
Journal: Cancer Research
Cancer Res (2015) 75 (3): 554–565.
https://doi.org/10.1158/0008-5472.CAN-14-2268
Published: 01 February 2015
View article titled, Gain of Glucose-Independent Growth upon Metastasis of Breast Cancer Cells to the Brain
Open the PDF for Gain of Glucose-Independent Growth upon Metastasis of Breast Cancer Cells to the Brain in another window
Includes: Supplementary data
Journal Articles

Abstract 1310: Liver X receptor agonist blocks pancreatic cancer cell proliferation.

Nicholes R. Candelaria, Sridevi Manchem, H Trang Vu, Jine Zheng, Chiara Gabbi, Prasenjit Dey, Husna Karaboga, Jean Lin, Lise-Lotte Vedin, Fei Su, Ka Liu, Philip Jonsson, Knut R. Steffensen, Jan-Åke Gustafsson, Chin-Yo Lin
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 1310.
https://doi.org/10.1158/1538-7445.AM2013-1310
Published: 15 April 2013
View article titled, Abstract 1310: Liver X receptor agonist blocks pancreatic cancer cell proliferation.
Journal Articles

Abstract 2156: Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAFV600E colorectal cancer models

Hong Yang, Brian Higgins, Kenneth Kolinsky, Jiakui Li, Richard Margolis, Zenaida Go, Aruna Railkar, Kathryn Packman, Gideon Bollag, Fei Su
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2156.
https://doi.org/10.1158/1538-7445.AM2012-2156
Published: 15 April 2012
View article titled, Abstract 2156: Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAF<sup>V600E</sup> colorectal cancer models
Journal Articles

Abstract 911: Vemurafenib FDG-PET preclinical imaging outcomes across BRAF V600E mutant and resistant tumors

Andreas R. Baudy, Taner Dogan, Judith E. Flores, Klaus P. Hoeflich, Fei Su, Nicholas van Bruggen, Simon P. Williams
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 911.
https://doi.org/10.1158/1538-7445.AM2012-911
Published: 15 April 2012
View article titled, Abstract 911: Vemurafenib FDG-PET preclinical imaging outcomes across BRAF V600E mutant and resistant tumors
Journal Articles

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Fei Su, William D. Bradley, Qiongqing Wang, Hong Yang, Lizhong Xu, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Min Jung Kim, Kerstin Trunzer, Richard J. Lee, Kathleen Schostack, Jade Carter, Thomas Albert, Soren Germer, Jim Rosinski, Mitchell Martin, Mary Ellen Simcox, Brian Lestini, David Heimbrook, Gideon Bollag
Journal: Cancer Research
Cancer Res (2012) 72 (4): 969–978.
https://doi.org/10.1158/0008-5472.CAN-11-1875
Published: 14 February 2012
View article titled, Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Open the PDF for Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su
Journal: Cancer Research
Cancer Res (2012) 72 (3): 779–789.
https://doi.org/10.1158/0008-5472.CAN-11-2941
Published: 31 January 2012
View article titled, Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Open the PDF for Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAFV600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

Brian Higgins, Kenneth Kolinksy, Zenaida Go, Hing Char, Richard Lee, Kathleen Schostack, Gideon Bollag, David Heimbrook, Fei Su, Kathryn E. Packman
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2562.
https://doi.org/10.1158/1538-7445.AM2011-2562
Published: 15 April 2011
View article titled, Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAF<sup>V600E</sup> inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model
Journal Articles

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Raman Iyer, Stanley Kolis, Sylvia Zhao, Richard Lee, Joseph F. Grippo, Kathleen Schostack, Mary Ellen Simcox, David Heimbrook, Gideon Bollag, Fei Su
Journal: Cancer Research
Cancer Res (2010) 70 (13): 5518–5527.
https://doi.org/10.1158/0008-5472.CAN-10-0646
Published: 30 June 2010
View article titled, RG7204 (PLX4032), a Selective BRAF<sup>V600E</sup> Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Open the PDF for RG7204 (PLX4032), a Selective BRAF<sup>V600E</sup> Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models in another window
Includes: Supplementary data
Journal Articles

Abstract #4420: PLX4032, a selective B-RafV600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models

Fei Su, Hong Yang, Brian Higgins, Kenneth Kolinsky, Richard Lee, Kathryn Packman, Kathleen Schostack, David Heimbrook, Gideon Bollag
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4420.
Published: 01 May 2009
View article titled, Abstract #4420: PLX4032, a selective B-Raf<sup>V600E</sup> inhibitor demonstrates potent antitumor activity in preclinical melanoma models